Anti-Diabetes Drug response study

Not Applicable

• Conditions: Health Condition 1: null- Type 2 Diabetes

• Registration Number: CTRI/2018/01/011508
• Lead Sponsor: Science and Engineering Research Board SERB

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 450

Inclusion Criteria

Clinically diagnosed drug naïve T2D patients (based on world health organization criteria)

Exclusion Criteria

Patients allergic to anti hyperglycemic drugs, type 1 diabetes mellitus, maturity onset diabetes of young (MODYs), gestational diabetes mellitus and secondary diabetes (e.g. pancreatitis, hemochromatosis), clinical renal or hepatic impairment, Cardiac problems (myocardial infarction, unstable angina pectoris), uncontrolled hypertension, non ketotic hyperosmolar coma or chronic diabetic complications, use of medications that could alter glucose metabolism, malignant diseases, hematological diseases, infected with hepatitis virus, psychosis, significant digestion, autoimmune diseases and resorption disturbances acute cerebrovascular accidents within the last 6 months will be excluded from the study.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The optimization of therapeutic strategy and the potential to expand to patient care.Timepoint: 3 years

Secondary Outcome Measures

Name	Time	Method
Better diagnoses, screening and management of diabetic patients in order to achieve individual care should benefit public healthTimepoint: After 3 years